Literature DB >> 11060086

Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics.

S C Lee1, A Antony, N Lee, J Leibow, J Q Yang, S Soviero, K Gutekunst, M Rosenstraus.   

Abstract

Version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for HCV were designed to improve on the performance of first version of the hepatitis C virus (HCV) tests. The new tests were calibrated in international units, the new commonly accepted standard unit of measurement for HCV RNA. The sensitivity of the qualitative tests was enhanced by modifying the specimen processing procedure to achieve a limit of detection 50 IU/ml. The limit of detection for the quantitative tests was 600 IU/ml. Modifications to the amplification reaction mixture and thermal cycling conditions enabled all genotypes to be amplified with similar efficiency. The quantitative tests exhibited a linear range extending from 500 to 500,000 IU/ml and excellent reproducibility, with coefficients of variation ranging from 18 to 39%, within the linear range. These data indicate that the version 2. 0 AMPLICOR HCV tests will improve diagnosis of HCV infection and will yield more-accurate titers for prognosis and for monitoring therapeutic efficacy, particularly at low viral loads. Furthermore, it will be possible to compare the performance characteristics and viral load measurements of AMPLICOR tests to those of other tests that adopt the international unit as the standard of measurement.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11060086      PMCID: PMC87559     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  37 in total

1.  Quantitative measurement of HCV RNA in the serum: a comparison of three assays based on different principles.

Authors:  T Ichijo; A Matsumoto; M Kobayashi; K Furihata; E Tanaka
Journal:  J Gastroenterol Hepatol       Date:  1997-07       Impact factor: 4.029

2.  A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C.

Authors:  M Rumi; E Del Ninno; M L Parravicini; R Romeo; R Soffredini; M F Donato; J Wilber; A Russo; M Colombo
Journal:  Hepatology       Date:  1996-12       Impact factor: 17.425

3.  Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group.

Authors:  T Poynard; J McHutchison; Z Goodman; M H Ling; J Albrecht
Journal:  Hepatology       Date:  2000-01       Impact factor: 17.425

4.  Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C.

Authors:  S Kakumu; T Aiyama; A Okumura; K Iwata; T Ishikawa; K Yoshioka
Journal:  J Gastroenterol Hepatol       Date:  1997-06       Impact factor: 4.029

5.  Serum levels of hepatitis C virus RNA predict non-response to interferon therapy: comparison of two commercial assays.

Authors:  R Soffredini; M G Rumi; E Del Ninno; M L Parravicini; A Russo; M Colombo
Journal:  J Viral Hepat       Date:  1999-01       Impact factor: 3.728

6.  Treatment of chronic hepatitis C with interferon-alpha by monitoring the response according to viraemia.

Authors:  P Bonetti; L Chemello; C Antona; A Breda; P Brosolo; P Casarin; C Crivellàro; G Donà; S Martinelli; R Rinaldi; V Zennaro; M Santonastaso; F Urban; P Pontisso; A Alberti
Journal:  J Viral Hepat       Date:  1997-03       Impact factor: 3.728

7.  Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level.

Authors:  G Yamada; M Takatani; F Kishi; M Takahashi; T Doi; T Tsuji; S Shin; M Tanno; M S Urdea; J A Kolberg
Journal:  Hepatology       Date:  1995-11       Impact factor: 17.425

8.  Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

Authors:  J Y Lau; G L Davis; J Kniffen; K P Qian; M S Urdea; C S Chan; M Mizokami; P D Neuwald; J C Wilber
Journal:  Lancet       Date:  1993-06-12       Impact factor: 79.321

9.  Detection of Chlamydia trachomatis in endocervical specimens by polymerase chain reaction.

Authors:  M J Loeffelholz; C A Lewinski; S R Silver; A P Purohit; S A Herman; D A Buonagurio; E A Dragon
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

10.  Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay.

Authors:  K K Young; R M Resnick; T W Myers
Journal:  J Clin Microbiol       Date:  1993-04       Impact factor: 5.948

View more
  46 in total

Review 1.  Laboratory assays for diagnosis and management of hepatitis C virus infection.

Authors:  Sandra S Richter
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

2.  Performance of the novel Qiagen artus QS-RGQ viral load assays compared to that of the Abbott RealTime system with genetically diversified HIV and hepatitis C Virus plasma specimens.

Authors:  Jan Felix Drexler; Ulrike Reber; Andrea Wuttkopf; Anna Maria Eis-Hübinger; Christian Drosten
Journal:  J Clin Microbiol       Date:  2012-03-07       Impact factor: 5.948

3.  Strengths and limitations of commercial tests for hepatitis C virus RNA quantification.

Authors:  Chihiro Morishima; Minjun Chung; Ka Wing Ng; Donald J Brambilla; David R Gretch
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

4.  Reduced PCR sensitivity due to impaired DNA recovery with the MagNA Pure LC total nucleic acid isolation kit.

Authors:  Tim Schuurman; Alex van Breda; Richard de Boer; Mirjam Kooistra-Smid; Marcel Beld; Paul Savelkoul; René Boom
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

5.  Hepatitis C virus RNA quantitation and degradation studies in whole blood samples in vitro.

Authors:  J Watson; S Graves; J Ferguson; C D'Este; R Batey
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

6.  Dynamic range of hepatitis C virus RNA quantification with the Cobas Ampliprep-Cobas Amplicor HCV Monitor v2.0 assay.

Authors:  Karine Gourlain; Alexandre Soulier; Bertrand Pellegrin; Magali Bouvier-Alias; Christophe Hézode; Françoise Darthuy; Jocelyne Rémiré; Jean-Michel Pawlotsky
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

7.  Rapid genotyping of hepatitis C virus by primer-specific extension analysis.

Authors:  Nick A Antonishyn; Vivian M Ast; Ryan R McDonald; Rabindra K Chaudhary; Lisa Lin; Anton P Andonov; Greg B Horsman
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

8.  Verification of an assay for quantification of hepatitis C virus RNA by use of an analyte-specific reagent and two different extraction methods.

Authors:  Michael S Forman; Alexandra Valsamakis
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

9.  Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment.

Authors:  Eiichi Ogawa; Norihiro Furusyo; Kazuhiro Toyoda; Hiroaki Taniai; Shigeru Otaguro; Mosaburo Kainuma; Masayuki Murata; Yasunori Sawayama; Jun Hayashi
Journal:  BMC Gastroenterol       Date:  2010-04-16       Impact factor: 3.067

10.  Diagnosing norovirus-associated infectious intestinal disease using viral load.

Authors:  Gemma Phillips; Ben Lopman; Clarence C Tam; Miren Iturriza-Gomara; David Brown; Jim Gray
Journal:  BMC Infect Dis       Date:  2009-05-14       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.